Fibroblast growth factor 21 alleviates idiopathic pulmonary fibrosis by inhibiting PI3K-AKT-mTOR signaling and stimulating autophagy
- 7 June 2024
- journal article
- research article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 273 (Pt 1) , 132896
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Jiangxi Province (20212BAB206094)
- Double Thousand Plan of Jiangxi Province (jxsq2020101090)
This publication has 41 references indexed in Scilit:
- Evaluation of prevention and treatment effects of fibroblast growth factor-21 in BLM-induced pulmonary fibrosisNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- FGF21 ameliorates hepatic fibrosis by multiple mechanismsMolecular Biology Reports, 2021
- Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosisActa Pharmaceutica Sinica B, 2021
- The interplay of ROS and the PI3K/Akt pathway in autophagy regulationBiotechnology and Applied Biochemistry, 2021
- Autophagy and Pulmonary Fibrosis2020
- Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapyApplied Microbiology and Biotechnology, 2019
- Identification of a crucial amino acid responsible for the loss of specifying FGFR1–KLB affinity of the iodinated FGF21Journal of Cellular Physiology, 2018
- FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitroBiomedicine & Pharmacotherapy, 2018
- Leptin promotes pulmonary fibrosis development by inhibiting autophagy via PI3K/Akt/mTOR pathwayBiochemical and Biophysical Research Communications, 2018
- M2 macrophages induce EMT through the TGF‐β/Smad2 signaling pathwayCell Biology International, 2017